Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Trial Profile

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2018

At a glance

  • Drugs Trilaciclib (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 23 May 2018 Planned End Date changed from 1 Jul 2019 to 1 Jan 2020.
    • 23 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2019.
    • 09 Apr 2018 According to a G1 Therapeutics media release, the company recently announced positive phase 2a topline data showing myelopreservation benefits in newly diagnosed, treatment-naive small cell lung cancer (SCLC) patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top